Latest News and Press Releases

Product revenue up 15%, compared to the June 2017 quarterPrescriptions filled were up 42% over last year and up 14% over the June 2017 quarter to 19,660EBITDA loss reduced to $2.3 millionCash on hand...

Brazilian Ministério da Saúde Approves Marketing of Sonoma Pharmaceuticals’ Products: Lasercyn™, Gramaderm®, Epicyn™ and Pediacyn™ Brazilian Dermatology Market Second Largest in the World Behind the...

PETALUMA, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that financial results for its fiscal second quarter 2018, ended...

PETALUMA, Calif., Oct. 03, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...

PETALUMA, Calif., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective...

Product revenue for first quarter up 49%, compared to the same period last year, driven by growth in U.S. dermatology salesConference Call Begins at 4:30pm EDT Today PETALUMA, Calif., Aug. 08, 2017 ...

PETALUMA, Calif., July 25, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal first quarter 2018, ended...

PETALUMA, Calif., July 13, 2017 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sonoma Pharmaceuticals, Inc., please note that in the first paragraph of the release...

Quarter ended June 30, 2017: Highest quarterly number of prescriptions filled 24% up over prior March quarter 201746% up over June quarter 2016 PETALUMA, Calif., July 13, 2017 (GLOBE NEWSWIRE) --...

PETALUMA, Calif., June 28, 2017 (GLOBE NEWSWIRE) -- A distinguished panel of U.S. dermatologists and plastic surgeons explored current literature to establish the value of hypochlorous acid (HOCl)...